Clinical trial
RE-DUAL PCI Real Life Registry Dual Therapy With Dabigatran/Ticagrelor Versus Dual Therapy With Dabigatran/Clopidogrel in ACS Patients With Indication for NOAC Undergoing PCI
NCT04688723 is registered in ClinicalTrials.gov with Zuyderland Medisch Centrum as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- RE-DUAL PCI Real Life Registry Dual Therapy With Dabigatran/Ticagrelor Versus Dual Therapy With Dabigatran/Clopidogrel in ACS Patients With Indication for NOAC Undergoing PCI
- Lead sponsor
- Zuyderland Medisch Centrum
- Phase
- Phase 4
- Overall status
- Unknown status
- Start date
- December 23, 2020
- Completion date
- July 1, 2023
- Enrollment
- 1,000 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.